Drug intelligence / Profile preview

SEP-380135

Development stage: Phase 1
Lead developer: Otsuka Holdings
Modality: Small Molecules
Administration: Oral

Overview

SEP-380135 is an orally administered small-molecule investigational agent that acts on the central nervous system and was discovered via PsychoGenics’ in vivo phenotypic SmartCube platform with AI, in collaboration with Sunovion/Sumitomo Pharma. Preclinical data suggest broad in vivo activity relevant to behavioral and psychological symptoms of dementia, including agitation/aggression, psychomotor hyperactivity, depression, and social interaction deficits, indicating potential utility in agitation and related neuropsychiatric symptoms; its precise molecular target and mechanism have not been disclosed. It is in Phase 1 clinical development in the United States, with Sumitomo Pharma/Otsuka listing it in pipeline materials for agitation and neuropsychiatric indications.[3][4][2][7][5]

Other names: 14C-SEP-380135

Targets

TAAR1 (Trace amine-associated receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on SEP-380135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEP-380135.

Explore the full profile